We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

When I wrote about consumer health and care group Ascendis several months ago, there was a little bit of drama surrounding the article. First, CEO Karsten Wellner called me up to challenge my comments. I had noted that the return on equity was low for a supposedly fast-growing company. I also believed that acquisitions were overpriced, and he assured me that Ascendis was not in fact paying too much for its foreign targets. And second, I berated the Business Day subeditors for a headline about the group "bleeding", when indeed the results were then looking okay. Fast forward to the next reporting period, and with the publication of Ascendis Health interim results to December 2017, the drama continues. First, Wellner is no longer the CEO, vacating this position almost instantly, being replaced by London-based Thomas Thomsen, who previously ran the European businesses of Ascendis. And second, huge apologies to the subs. They seemed to know what was ahead as Ascendis is now indeed a bit...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now

Would you like to comment on this article?
Register (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.

Commenting is subject to our house rules.